Objective:Toexploretheclinicopathologicalfeatures,surgicaltreatmenttechniques,andprognosticriskfactorsofintrahepaticcholangiocarcinoma(ICC).Methods:Atotalof104ICCcaseswerecollectedfromJanuary2008toDecember2013atTianjinMedicalUniversityCancerInstituteandHospitalandpidedintothehepatichilumlymphadenectomy(HLL,21cases),extendedhepatichilumlymphadenectomy(EHLL,12cases),andnon-lymphadenectomy(NL,71cases)groups.Theclinicaldataofthepatientswereretrospectivelyanalyzed,andtheprognosticdifferenceswerecomparedamongdifferentgroups.Results:The1-,2-,and3-yearoverallsurvival(OS)ratesofallcaseswere72.1%,56.1%,and43.7%,respectively.Themediansurvivaldurationwas34months.The1-,2-,and3-yearOSratesoftheHLLgroup(42.9%,28.6%,and28.6%,respectively)weresignificantlylowerthanthoseoftheNLgroup(78.9%,62.5%,and47.8%,respectively).Meanwhile,the1-,2-,and3-yearOSratesoftheEHLLgroup(75.0%,56.1%,and33.3%,respectively)werenotsignificantlydifferentfromthoseoftheothertwogroups.Univariateanalysisshowedthatage,gender,AmericanJointCommitteeonCancer(AJCC)stage,differentiation,ferritin(Fer),carbohydrateantigen19-9(CA19-9)andcarcinoembryonicantigen(CEA)levels,lymphnodemetastasis(LNM),andlymphnodedissection(LND)wereprognosticfactorsforthelong-termsurvivalofICC.Meanwhile,multivariateanalysisrevealedthatage,AJCCstage,differentiation,Ferlevels,andLNMwereindependentriskfactorsforsurvival.Conclusions:ICCpatientswillnotbenefitfromlymphadenectomyintheabsenceofLNM.However,systematiclymphadenectomymayimproveICCoutcomesifthelocationoflymphaticmetastasisisknown.Age,AJCCstage,differentiation,Ferlevel,andLNMareindependentriskfactorsforsurvivalinICC.
